African Arguments

Top Menu

  • About Us
  • Write for us
  • Contact us
  • Advertise
  • Newsletter
  • RSS feed
  • Donate
  • Fellowship

Main Menu

  • Home
  • Country
    • Central
      • Cameroon
      • Central African Republic
      • Chad
      • Congo-Brazzaville
      • Congo-Kinshasa
      • Equatorial Guinea
      • Gabon
    • East
      • Burundi
      • Comoros
      • Dijbouti
      • Eritrea
      • Ethiopia
      • Kenya
      • Rwanda
      • Seychelles
      • Somalia
      • Somaliland
      • South Sudan
      • Sudan
      • Tanzania
      • Uganda
      • Red Sea
    • North
      • Algeria
      • Egypt
      • Libya
      • Morocco
      • Tunisia
      • Western Sahara
    • Southern
      • Angola
      • Botswana
      • eSwatini
      • Lesotho
      • Madagascar
      • Malawi
      • Mauritius
      • Mozambique
      • Namibia
      • South Africa
      • Zambia
      • Zimbabwe
    • West
      • Benin
      • Burkina Faso
      • Cape Verde
      • Côte d’Ivoire
      • The Gambia
      • Ghana
      • Guinea
      • Guinea Bissau
      • Liberia
      • Mali
      • Mauritania
      • Niger
      • Nigeria
      • São Tomé and Príncipe
      • Senegal
      • Sierra Leone
      • Togo
  • Politics
    • Elections Map
  • Economy
  • Society
    • Climate crisis
  • Culture
  • Specials
    • From the fellows
    • Radical Activism in Africa
    • On Food Security & COVID19
    • #EndSARS
    • Covid-19
    • Travelling While African
    • From the wit-hole countries…
    • Living in Translation
    • Red Sea
    • Beautiful Game
  • Podcast
    • Into Africa Podcast
    • Africa Science Focus Podcast
    • Think African Podcast
  • Debating Ideas
  • About Us
  • Write for us
  • Contact us
  • Advertise
  • Newsletter
  • RSS feed
  • Donate
  • Fellowship

logo

Header Banner

African Arguments

  • Home
  • Country
    • Central
      • Cameroon
      • Central African Republic
      • Chad
      • Congo-Brazzaville
      • Congo-Kinshasa
      • Equatorial Guinea
      • Gabon
    • East
      • Burundi
      • Comoros
      • Dijbouti
      • Eritrea
      • Ethiopia
      • Kenya
      • Rwanda
      • Seychelles
      • Somalia
      • Somaliland
      • South Sudan
      • Sudan
      • Tanzania
      • Uganda
      • Red Sea
    • North
      • Algeria
      • Egypt
      • Libya
      • Morocco
      • Tunisia
      • Western Sahara
    • Southern
      • Angola
      • Botswana
      • eSwatini
      • Lesotho
      • Madagascar
      • Malawi
      • Mauritius
      • Mozambique
      • Namibia
      • South Africa
      • Zambia
      • Zimbabwe
    • West
      • Benin
      • Burkina Faso
      • Cape Verde
      • Côte d’Ivoire
      • The Gambia
      • Ghana
      • Guinea
      • Guinea Bissau
      • Liberia
      • Mali
      • Mauritania
      • Niger
      • Nigeria
      • São Tomé and Príncipe
      • Senegal
      • Sierra Leone
      • Togo
  • Politics
    • Elections Map
  • Economy
  • Society
    • Climate crisis
  • Culture
  • Specials
    • From the fellows
    • Radical Activism in Africa
    • On Food Security & COVID19
    • #EndSARS
    • Covid-19
    • Travelling While African
    • From the wit-hole countries…
    • Living in Translation
    • Red Sea
    • Beautiful Game
  • Podcast
    • Into Africa Podcast
    • Africa Science Focus Podcast
    • Think African Podcast
  • Debating Ideas
Covid-19Top story

Funding for COVID-19 treatments: No one is safe until everyone is

By Philippe Duneton & Paul Schreier
October 16, 2020
851
0
Share:
COVID-19 testing in Madagascar. Credit: World Bank / Henitsoa Rafalia.

Without cash, the chance to ensure fair access to COVID-19 treatments for all is disappearing fast. $4 billion needs to arrive in the next two months.

COVID-19 testing in Madagascar. Credit: World Bank / Henitsoa Rafalia.

COVID-19 testing in Madagascar. Credit: World Bank / Henitsoa Rafalia.

As many countries around the world are now experiencing the predicted second wave of COVID-19, their populations could be forgiven for experiencing a sense of déjà-vu. But there is one clear difference this time. As we approach the end of 2020, we know so much more about the medicines, diagnostic tests and vaccines that will help us bring an end to this pandemic.

For example, we’ve seen that repurposed drugs such as dexamethasone can save the lives of ventilated patients. And just last month, we saw the game-changing launch of new Rapid Diagnostic Tests that give results in just fifteen minutes. Clinical trials of innovations such as monoclonal antibodies are showing promising results.

At this moment in time, wealthier nations are making deals to reserve drugs, vaccines and tests that they hope will allow their populations to get back to normality and reduce the death toll from COVID-19.

This response is understandable. But the current trajectory risks leaving countries with limited purchasing power crowded out at the back of a growing queue.

The Access to COVID Tools Accelerator (ACT-A) is a global, collaborative effort which was set up to ensure that the solutions to ending this pandemic reach every corner of the world, with the key principle that “no one is safe until everyone is”. Investment in equitable access to COVID-19 tools should not be seen by wealthy nations as a charitable donation, but rather an essential investment to ensure that their populations – as well as others – are protected.

To provide treatments around the world we need $7.2 billion. So far, only $300 million has been pledged – with vaccines already having received around six times more funding than treatments.

It is imperative to recognise that a vaccine, if and when it comes, will not be a panacea. It will take months and maybe years to roll out across the globe and the initial programme may not be completely effective. This means that people will continue to fall ill and will continue to need rapid diagnosis and appropriate treatment.

We cannot put all our eggs into this one vaccine basket. We need a three-pronged end-to-end strategy that works to: identify cases through rapid testing; treat COVID-19 more effectively with ever-evolving medicines; and vaccinate populations against future infections.

By the end of the year, we will have a clear idea of which treatments work, and how and where they can be used. But the simple fact is that we are running out of time.

Our fear is that when a ground-breaking new medicine or test emerges, we will simply not have the funds to make sure that everyone has access. Wealthy nations have already placed their orders with manufacturers across the world. We need to do the same on behalf of low-and-middle countries now – if we wait even until the start of 2021, it will be too late.

Last month, G20 Health and Finance Ministers gave their strong support to ACT-A. They emphasised the need for a global response and the important role the partnership plays in “accelerating research, development, manufacturing and distribution of COVID-19 diagnostics, therapeutics and vaccines”. They encouraged countries to make voluntary contributions to the ACT-A facility – and some have already done so.

European Commission President Ursula von der Leyen recently referenced in her State of the Union address the €16 billion ($18.7 billion) raised through an EU-led mobilisation effort earlier this year. But despite the impressive pledges made at this event, the funds have simply not been forthcoming. Plenty of warm words have been expressed by leaders from all corners of the globe. But these need to now turn into concrete action and money – and soon.

As leaders of the ACT-A Therapeutics partnership, we are very concerned about the significant shortfall that is emerging, particularly for COVID treatments. $4 billion of the required $7.2 billion total needs to arrive in the next two months.

Without cash on the table, the chance to ensure fair access for all is disappearing fast. The economic outlook is bleak for all nations, but leaders cannot afford to put off financing these vital measures. To do so would result in catastrophic consequences for whole populations, prolonging the pandemic and the economic havoc it has wreaked.

This crisis needs a moment of historic political and financial leadership. No leader can tell their populations that they are protected while other nations are left exposed.

The time for warm words is over. The time for action is now.


 

Previous Article

Why #EndSARS won’t quit

Next Article

Podcast: Virtues of virtual election monitoring

Philippe Duneton & Paul Schreier

Dr Philippe Duneton is the Executive Director a.i .of Unitaid. Paul Schreier is the Chief Operating Officer of Wellcome.

Leave a reply Cancel reply

  • Politics

    Tanzania: as constitutional reform stalls, Jakaya Kikwete risks losing his legacy – By Erick Kabendera

  • Covid-19MalawiOn Food Security & COVID19Top story

    Malawi: COVID-19 hindered business for farmers. They found solutions.

  • Will relations between Presidents Yoweri Museveni Paul Kagame worsen with the trial of Kayihura? Credit: Rwanda govt.
    Editor's PicksPoliticsRwandaUganda

    Uganda: A police chief on trial and deepening suspicions with Rwanda

Subscribe to our newsletter

Click here to subscribe to our free weekly newsletter and never miss a thing!

  • 81664
    Followers

Find us on Facebook

Interactive Elections Map

Keep up to date with all the African elections.

Popular articles

  • Rasha Mekky with her adopted son Mostafa. Credit: Rasha Mekky.

    “People said it’s haram”: Happy mums show reality of adoption in Egypt

  • Have you seen Dakan, the Guinean queer classic? It changed my life.

  • President Cyril Ramaphosa (left) with his predecessor, former President Jacob Zuma in 2017. Credit: GCIS.

    What did we learn from South Africa’s exhaustive state capture commission?

  • Girls line up during a basketball drill in Mogadishu, Somalia. Credit: AU UN IST/Tobin Jones.

    To counter al-Shabaab, Somalia’s new govt must do something for the kids

  • President João Lourenço of Angola on a state visit to South Africa in 2017. Credit: GCIS.

    Angola’s regime pushes back against a growing and united opposition

Brought to you by


Creative Commons

Creative Commons Licence
Articles on African Arguments are licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
  • Cookies
  • Privacy Policy
  • Terms & Conditions
  • en English
    am Amharicar Arabicny Chichewazh-CN Chinese (Simplified)en Englishfr Frenchde Germanha Hausait Italianpt Portuguesest Sesothosn Shonaes Spanishsw Swahilixh Xhosayo Yorubazu Zulu
© Copyright African Arguments 2020
Cleantalk Pixel
By continuing to browse the site you are agreeing to our use of cookies.
en English
am Amharicar Arabicny Chichewazh-CN Chinese (Simplified)en Englishfr Frenchde Germanha Hausait Italianpt Portuguesest Sesothosn Shonaes Spanishsw Swahilixh Xhosayo Yorubazu Zulu
African Arguments wants to hear from you!

Take 5 minutes to fill in this short reader survey and you could win three African Arguments books of your choice…as well as our eternal gratitude.